Recent FDA action (through April 2009) related to alglucosidase alfa, bosentan, cetuximab, doxepin, telavancin, quetiapine extended-release, oxycodone/niacin, and EUR-1073
Complete response
Priority review
Orphan drug designations
Get the latest industry news, event updates, and more from Managed healthcare Executive.